FindTrial
Sign In

Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy

Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07555301
Acronym
SWIAN
Enrollment
50
Registered
2026-04-29
Start date
2026-06-01
Completion date
2029-12-31
Last updated
2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA Nephropathy (IgAN)

Brief summary

An observational study tracking the clinical course of patients with IgA nephropathy.

Detailed description

The aim is to monitor the clinical progression of patients with histologically confirmed IgA nephropathy in terms of GFR and proteinuria.

Interventions

DRUGsparsentan

Follow up observation of patients with IgA Nephropathy on sparsentan regarding Albuminuria and GFR

Sponsors

Waid City Hospital, Zurich
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* IgA Nephropathy, Use of Sparsentan

Exclusion criteria

* age \< 18y

Design outcomes

Primary

MeasureTime frameDescription
Change of Albuminuria36 monthsWhat is the impact of sparsentan on Albuminuria

Countries

Switzerland

Contacts

CONTACTAndi Schleich
Andreas.schleich@stadtspital.ch+41 44 416 21 55

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 30, 2026